IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer

Hassan Yousefi1,2, Majid Momeny1, Seyed H Ghaffari1

  • 11 Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Tumori
|July 20, 2018
PubMed
Abstract

Insights

Interleukin-6 (IL-6) signaling drives chemoresistance in epithelial ovarian cancer (EOC). Blocking IL-6 with tocilizumab resensitizes resistant EOC cells to chemotherapy, offering a new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Epithelial ovarian cancer (EOC) is a leading cause of cancer death globally.
  • Most EOC patients develop chemoresistant disease, necessitating novel therapeutic strategies.
  • Overcoming therapy resistance is critical for improving EOC patient outcomes.

Purpose of the Study:

  • To investigate the expression of interleukin-6 (IL-6) and its receptor (IL-6R) in EOC cell lines.
  • To correlate IL-6/IL-6R expression with chemosensitivity in EOC.
  • To evaluate the therapeutic potential of targeting the IL-6 pathway in chemoresistant EOC.

Main Methods:

  • Quantitative reverse transcription polymerase chain reaction (RT-qPCR) to measure IL-6 and IL-6R expression.
  • MTT assay to determine chemosensitivity of EOC cell lines.
  • Treatment of EOC cells with tocilizumab (anti-IL-6R antibody) and carboplatin.

Main Results:

  • Higher IL-6 and IL-6R expression was observed in therapy-resistant EOC cells compared to sensitive cells.
  • Elevated IL-6/IL-6R levels correlated with resistance to specific chemotherapeutic agents.
  • Combination therapy with tocilizumab and carboplatin synergistically inhibited EOC cell growth and proliferation.
  • The NF-κB pathway was identified as a key regulator of IL-6 gene expression.

Conclusions:

  • IL-6 signaling blockade using tocilizumab may resensitize chemoresistant EOC cells to existing chemotherapeutics.
  • Targeting the IL-6 pathway represents a promising strategy to overcome treatment resistance in EOC.
  • Further clinical investigation of IL-6 pathway inhibitors in EOC is warranted.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
C4 Pathway and CAM01:27

C4 Pathway and CAM

Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
49.2K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.9K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.1K
Other Glycolytic Pathways01:24

Other Glycolytic Pathways

The pentose phosphate pathway (PPP) operates in parallel with glycolysis, facilitating the metabolism of both pentoses and glucose. This pathway consists of two distinct phases: the oxidative and non-oxidative phases. While it does not directly generate ATP, the intermediates formed during the process can integrate into glycolysis, contributing to cellular energy metabolism when required.Oxidative Phase: NADPH ProductionThe oxidative phase of the pentose phosphate pathway is primarily...
929
Therapeutic Communication01:30

Therapeutic Communication

Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.5K